$ALT

Altimmune, Inc. (ALT) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 24, 2026, the Board of Directors (the “Board”) of Altimmune, Inc. (the “Company”) appointed Richard Menziuso a

Novo Nordisk (NVO) announced plans for larger acquisitions and over five multi-blockbuster launches by 2030, targeting $23B in pipeline sales by 2035. Shares of smaller obesity-focused companies Viking Therapeutics (VKTX), Structure Therapeutics (GPCR), and Altimmune (ALT) rose, while NVO shares fell 8%. NVO's CagriSema treatment showed promising weight loss results, but investors remain cautious.

Altimmune (ALT) shares rose 14.2% since its last earnings report, outperforming the S&P 500. The company reported a narrower Q2 2026 loss of 12 cents per share, beating estimates, but no revenue. R&D expenses increased 8.2% YoY, and cash reserves grew to $519M. Analysts revised estimates upward by 11.29%. The stock has a Zacks Rank #3 (Hold).

Altimmune (ALT) reported Q2 results, highlighting progress in three liver disease trials. The company launched a global Phase 3 trial for MASH, reported positive Phase 2 data for alcohol use disorder, and completed enrollment for a Phase 2 trial in alcohol-associated liver disease. Altimmune has no approved products and reported a net loss of $22.8 million, with cash reserves of $519 million as of June 30.

Altimmune has begun a Phase 3 trial for pemvidutide, a dual-hormone drug targeting metabolic dysfunction-associated steatohepatitis (MASH). The drug uniquely balances glucagon and GLP-1 receptor activation, aiming to address liver fat and fibrosis. The trial's success could validate its differentiation in a crowded market. Altimmune's valuation is highly dependent on the outcome, with a price-to-sales ratio of 72.5x.

$ALT stock rose 7% today with $4.17M in trading volume. Insiders made 6 purchases in the last 6 months. 142 institutional investors increased their positions in Q2 2026. Analysts set price targets ranging from $10 to $20.

Lululemon (LULU), Lucid (LCID), and Altimmune (ALT) hit 52-week lows due to leadership uncertainty, financial strain, and strategic concerns. LULU dropped 13% after naming a new CEO, LCID fell 9% amid funding and production cost worries, and ALT declined 16% following a stock offering. Uber owns 11.52% of LCID.

Durso Jerome Benedict (President and CEO) purchased 15,000 shares of Altimmune, Inc. (ALT) at $2.95 on 2026-08-13.

Altimmune (NASDAQ:ALT) said patients on GLP-1 therapies at antidiabetic doses may be included in its PERFORMA trial, but those on Rezdiffra will be excluded to protect a 52-week biopsy endpoint. PERFORMA 52-week data are expected in 2029. In Phase II AUD RECLAIM, pemvidutide met primary and secondary endpoints, including a 9.1% body-weight reduction. Q2 net loss was $22.8M and cash was $519M.

Altimmune (Nasdaq: ALT) reported Q2 2026 results and a business update. The company initiated the global PERFORMA Phase 3 MASH trial, reported positive topline RECLAIM Phase 2 AUD data, and completed enrollment in the RESTORE Phase 2 ALD trial. Cash, cash equivalents and investments were $519 million as of June 30, 2026. R&D was $18.7 million and net loss $22.8 million.